Néstor Báez-Ferrer

Dr. Néstor Báez-Ferrer


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
Sergio RodríguezSergio Rodríguez
Sergio Rodríguez
RDRocío Díaz
Rocío Díaz
DHDaniel Hernandez-Vaquero
Daniel Hernandez-Vaquero
Background: Whether or not inhalation of airborne desert dust has adverse health effects is unknown. The present study, based on a systematic review and meta-analysis, was carried out to assess the influence desert dust on cardiovascular mortality, acute coronary syndrome, and heart failure. Methods: A systematic search was made in PubMed and Embase databases for studies published before March 2020. Studies based on daily measurements of desert dust were identified. The meta-analysis evaluated the impact of desert dust on cardiovascular events the same day (lag 0) of the exposure and during several days after the exposure (lags 1 to 5). The combined impact of several days of exposure was also evaluated. The incidence rate ratio (IRR) with 95% confidence intervals (CI) was calculated using the inverse variance random effects method. Results: Of the 589 identified titles, a total of 15 studies were selected. The impact of desert dust on the incidence of cardiovascular mortality was statistically significant (IRR = 1.018 (95%CI 1.008–1.027); p < 0.001) in lag 0 of the dust episode, in the following day (lag 1) (IRR = 1.005 (95%CI 1.001–1.009); p = 0.022), and during both days combined (lag 0–1) (IRR = 1.015 (95%CI 1.003–1.028); p = 0.014). Conclusions: The inhalation to desert dust results in a 2% increase (for every 10 µg/m3) in cardiovascular mortality risk.

30 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
Sergio RodríguezSergio Rodríguez
Sergio Rodríguez
Pablo AvanzasPablo Avanzas
Pablo Avanzas
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
EWErnest Werner
Ernest Werner
Recent studies have found increases in the cardiovascular mortality rates during poor air quality events due to outbreaks of desert dust. In Tenerife, we collected (2014–2017) data in 829 patients admitted with a heart failure diagnosis in the Emergency Department of the University Hospital of the Canaries. In this region, concentrations of PM10 and PM2.5 are usually low (~20 and 10 µg/m3), but they increase to 360 and 115 μg/m3, respectively, during Saharan dust events. By using statistical tools (including multivariable logistic regressions), we compared in-hospital mortality of patients with heart failure and exposure to PM10 and PM2.5 during dust and no-dust events. We found that 86% of in-hospital heart failure mortality cases occurred during Saharan dust episodes that resulted in PM10 > 50 µg/m3 (interquartile range: 71–96 µg/m3). A multivariate analysis showed that, after adjusting for other covariates, exposure to Saharan dust events associated with PM10 > 50 µg/m3 was an independent predictor of heart failure in-hospital mortality (OR = 2.79, 95% CI (1.066–7.332), p = 0.03). In conclusion, this study demonstrates that exposure to high Saharan dust concentrations is independently associated with in-hospital mortality in patients with heart failure.

30 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
DHDaniel Hernandez-Vaquero
Daniel Hernandez-Vaquero
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
RDRocío Díaz
Rocío Díaz
Russel ReiterRussel Reiter
Russel Reiter
Background: Matrix metalloproteinase-9 (MMP-9) is crucial in tissue remodeling after an adverse cardiac event. In experimental studies, melatonin has been found to attenuate MMP-9 activation. The present study assessed the effects of systemic melatonin administration on the prognosis of patients with acute myocardial infarction (AMI) successfully treated with primary percutaneous coronary intervention, and to examine the effects on MMP-9 levels. Methods: We conducted a randomized controlled trial, enrolling patients who underwent primary percutaneous coronary intervention due to AMI. They were assigned to two groups for melatonin or placebo. The primary endpoint was a combined event of mortality and heart failure readmission at 2 years. The secondary endpoint was the levels of MMP-9 after the percutaneous coronary intervention. Results: Ninety-four patients were enrolled, 45 in the melatonin group and 49 in the control group. At 2 years of follow-up, 13 (13.8%) patients suffered the primary endpoint (3 deaths and 10 readmissions due to heart failure), 3 patients in the melatonin group and 10 in the placebo group. The difference in the restricted mean survival time was 87.5 days (p = 0.02); HR = 0.3 (95% CI 0.08–1.08; p = 0.06); Log-rank test 0.04. After controlling for confounding variables, melatonin administration reduced MMP-9 levels to 90 ng/mL (95% CI 77.3–102.6). Conclusions: This pilot study demonstrated that compared to placebo, melatonin administration was associated with better outcomes in AMI patients undergoing primary percutaneous coronary intervention.

16 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
ALAlejandro Lemus-Martín
Alejandro Lemus-Martín
MCMaría Beatriz Castro-Hernández
María Beatriz Castro-Hernández
Pablo AvanzasPablo Avanzas
Pablo Avanzas
SGSusana Martínez González
Susana Martínez González
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
Background/Objectives: Heart failure (HF) is associated with chronic systemic inflammation, resulting in increased mortality. The intestinal microbiota can modulate systemic inflammation, and changes in the microbiota have been observed in patients with HF. Methods: A systematic search was performed in PubMed/MEDLINE up until July 2025 for studies comparing the intestinal microbiota between patients with HF and healthy controls (HCs). The PRISMA (Preferred Reporting Items for Systemic reviews and Meta-Analyses) criteria were used. The risk of bias was evaluated with the Newcastle–Ottawa scale for cross-sectional studies. Results: Fourteen studies with 1167 participants (550 patients with HF and 617 HC) were included. The patients with HF had less alpha and beta diversity compared with HC. In turn, the patients with HF presented an increase in proinflammatory bacteria belonging to the genera Streptococcus and Escherichia-Shigella, and a decrease in bacteria with anti-inflammatory effects, pertaining to the genera Faecalibacterium, Blautia and Lachnospira. Conclusions: Patients with HF present an altered intestinal microbiota, favoring the growth of bacteria that increase systemic inflammation through their metabolic activity. Modulation of the intestinal microbiota through different approaches is seen as a new therapeutic target in HF.

Verified
Journal Article
Open access
PDF file
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
Pablo AvanzasPablo Avanzas
Pablo Avanzas
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
Sergio RodríguezSergio Rodríguez
Sergio Rodríguez
DHDaniel Hernandez-Vaquero
Daniel Hernandez-Vaquero
Aims: The main objective of this study is to determine whether exposure to Saharan dust causes airway inflammation and oxidative stress in patients with stable chronic heart failure (HF) and a left ventricular ejection fraction of less than 40%. Methods: A longitudinal study design is used, involving the inclusion of 40 patients with stable chronic HF and a left ventricular ejection fraction of less than 40%. Four sputum samplings will be taken from each patient, with one sampling taken each week over four consecutive weeks. The sputum samples will be used to analyze the degree of inflammation and oxidative stress. Air quality monitoring stations will be used to analyze the particulate matter (PM) exposure of each patient. The intrusion of desert dust will be identified using meteorological models. There will be 160 scheduled samplings in 40 patients with chronic HF. Mixed regression models will be used to assess the influence of the concentrations of PM (from the episodes of desert dust) upon the airway inflammation and oxidative stress markers. Conclusion: The results of this study will test the hypothesis that exposure to high concentrations of Saharan dust affects the normal function of the respiratory epithelium due to the imbalance between the production of free radicals and antioxidant enzymes, thus causing increased pulmonary inflammation and oxidative stress in patients with HF that in turn may facilitate decompensations of their background disease condition.

1 January 2020 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
Alberto Dominguez-RodriguezAlberto Dominguez-Rodriguez
Alberto Dominguez-Rodriguez
Pablo AvanzasPablo Avanzas
Pablo Avanzas
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
NBNéstor Báez-Ferrer
Néstor Báez-Ferrer
Fernando Martin-SanchezFernando Martin-Sanchez
Fernando Martin-Sanchez
ÒMÒscar Miró
Òscar Miró
Adherence to the Mediterranean diet (MedDiet) has been associated with prolonged survival in older individuals. However, it is unknown whether adherence to MedDiet is associated with the prognosis in older patients scheduled to undergo cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the association between adherence to the MedDiet and clinical outcomes at 12 months follow-up after CRT implantation in older patients. Patients adherents to the MedDiet, defined as ≥ 9 of 14 points using the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Study) questionnaire, was assessed before device implantation in patient's ≥ 70 years candidates for CRT. The primary outcome was a combined endpoint at 12 months follow-up after CRT implantation, defined as cardiovascular death, cardiac transplantation or decompensated heart failure. The cohort study consisted of 284 patients with a mean age of 73 ± 3 years. One hundred and fifty-nine (55.9%) patients were classified as adherent to the MedDiet. Seventy (24.6%) patients showed the combined endpoint at one year follow-up. Subjects who did not developed the combined endpoint had higher proportion of adherent patients to the MedDiet compared to patients who developed the combined endpoint (85% vs 67.1%, p = 0.002). After adjustment by possible confounders, the adherence to the MedDiet was a protective and significant predictor of the combined endpoint (HR = 0.42, 95% CI 0.22-0.81; p = 0.01). Adherence to the MedDiet is inversely associated with outcome in older patients following CRT.